1.

一线应用贝伐珠单抗与含铂双药联合化疗的Ⅲ期随机对照研究

Phase 3 randomized studies of bevacizumab and platinum based double agents chemotherapy as front line treatment for advanced NSCLC

Study	Regimen	n	ORR (%)	PFS (mon)	OS (mon)
ORR: objective response rate; PFS: progression free survival; OS: overall survival; NSCLC: non-small cell lung cancer.
ECOG 4599	Carboplatin+paclitaxel+bevacizumab 15 mg/kg	434	35.0	6.2	12.3
	Carboplatin+paclitaxel	444	15.0, P < 0.001	4.5, HR=0.66	10.3, HR=0.79
AVAiL	Cisplatin+gemcitabine+bevacizumab 15 mg/kg	351	34.6, P=0.046	6.5, HR=0.82	13.4, HR=1.03
	Cisplatin+gemcitabine+bevacizumab 7.5 mg/kg	345	37.8, P=0.000, 3	6.7, HR=0.75	13.6, HR=0.93
	Cisplatin+gemcitabine	347	21.6	6.1	13.1
PointBreak	Carboplatin+pemetrexed+bevacizumab 15 mg/kg bevacizumab+pemetrexed maintenance	472	34.1	6.0, HR=0.83	12.6, HR=0.949
	Ccarboplatin+paclitaxel+bevacizumab 15 mg/kg bevacizumabmaintenance	467	33.0	5.6	13.4
AVAPERL	Cisplatin+pemetrexed+bevacizumab 7.5 mg/kg then randomization	376	22.7
	Bevacizumab 7.5 mg/kg+pemetrexed maintenance	128		7.4, HR=0.48	17.1, HR=0.87
	Bevacizumab 7.5 mg/kg maintenance	125		3.7	13.2
BEYOND	Carboplatin+paclitaxel+bevacizumab 15 mg/kg	138	54.0, P < 0.001	9.2, HR=0.40	24.3, HR=0.68
	Carboplatin+paclitaxel+placbo	138	26	6.5	17.7
PRONOUNCE	Carboplatin+pemetrexed pemetrexed maintenance	182	23.6, P=0.414	4.44, HR=1.06	10.5, HR=1.07
	Carboplatin+paclitaxel+bevacizumab 15 mg/kg bevacizumab maintenance	179	27.4	5.49	11.7
ACRIN 5508	Carboplatin+paclitaxel+bevacizumab 15 mg/kg then randomization	1, 516	30.3
	Bevacizumab maintenance	287	12.5	4.2	14.4
	Pemetrexed maintenance	294	18.7	5.1, HR=0.85	15.9, HR=0.86
	Bevacizumab+pemetrexed maintenance	293	21.2	7.5, HR=0.82	16.4, HR=0.9
COMPASS	Carboplatin+pemetrexed+bevacizumab 15 mg/kg then randomization	856
	Bevacizumab maintenance	295		4.0	19.6
	Bevacizumab+pemetrexed maintenance	299		5.7, HR=0.67	23.3, HR=0.87